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ABSTRACT
The obiective is to review β-adrenergic receptors and mecha-
nisms in the immediate and late bronchial reaction in asthma 
and the new long-acting B-agonist. This will be discussed in 
light of the controversy of the potential adverse effect of regular 
use of long-acting R-agonists. We studied the effect of for-
moterol on the late asthmatic response (LAR) and airway 
inflammation in guinea-pigs. Formoterol suppressed the LAR, 
antigen-induced airway inflammation and hyperresponsive-
ness, although isoproterenol failed to inhibit these parameters.
β-Adrenergic hyporesponsiveness, and cholinergic and α-
adrenergic hyperresponsiveness have been implicated in the
pathogenesis of asthma. A decrease in β-adrenoreceptor func-
tion can result either from exogenously administered β-agonist
or from exposure to allergens resulting in a late bronchial reac-
tion. There is increasing evidence that eosinophils, 
macrophages, and lymphocytes which are of primary impor-
tance in the late bronchial reaction are also modulated by β2-
adrenoreceptors. In functional studies of guinea-pig or human 
isolated trachea and lung parenchyma, PAF and certain 
cytokines significantly reduced the potency of isoproterenol to 
reverse methacholine- or histamine-induced contraction. The
exect of glucocorticoids on pulmonory β-adrenergic receptors
and responses suggests an important role for glucocorticoids to
increose β-adrenergic receptors and responsiveness.
Key words: airway inflammation, asthma, β-adrenergic
receptors, formoterol, late bronchial reaction.
THE CONTROVERSY REGARDING CONTINUOUS USE
OF β-ADRENERGIC AGONISTS
There is currently some degree of confusion in the minds of the 
public, as well as in the minds of some physicians, whether fatal
or near fatal asthma attacks are due to under-treatment or over-
treatment.1 This is particularly true for the current and recurrent 
controversy about the use of inhaled, self-administered, high
doses of β-agonist drugs by patients with asthma before they are
admitted to the hospital or die.
 There has been extensive investigation into the recent 
increase in deaths caused by asthma in the United States,2 the 
United Kingdom and New Zealand.3 However, the cause of the 
increasing number of deaths from asthma is still undetermined. 
The question of increased mortality from asthma as a result of 
under-treatment versus over-treatment is particuarly important 
because of the recent availability of powerful, new, long-acting,
inhQled β-agonists. It hos been argued thot the overuse f β-
agonist drugs may temporarily relieve symptoms without treat-
ing the underlying inflammatory process and may result in the 
administration of oxygen and life-saving anti-inflammatory cor-
ticosteroids being delayed.4,5
  Regular treatment with isoproterenol6 and fenoterol7 has been 
associated with worsening of asthma and a predisposition to 
increased risk of life-threatening attacks.5 This has led some authors 
to suggest that over-treatment with these agents is detrimental.
 Molfino et al.1 have attempted to address the role of cardio-
toxicity associated with these agents, particularly in the presence 
of hypoxemia. Although cardiotoxicity has been demonstrated in 
animals,8 it has been difficult to assess in patients presenting with 
life-threatening attacks of asthma. The authors evaluated 10 
asthmatic patients with respiratory arrest and analyzed the clini-
cal and laboratory characteristics of these patients. Molfino et al. 
suggested that asphyxia rather than cardiac complications 
caused by bronchodilator therapy is the cause for the over-
whelming majority of deaths secondary to bronchial asthma in 
young and middle-aged patients. They concluded that under-
treatment as evidenced by severe asphyxia and hypoxia rather 
than over-treatment is one of the major factors involved in the 
increased number of deaths from asthma.
  The report by Sears et al. on the worsening of asyhma from the
regularuse of β-agonists has sparked the debate of the beneficial
versus detrimental effects of the powerful new long-acting β2-ago-
nist.7 They reported that on-demand, inhaled, bronchodilator
therapy was more effective than the regular use of inhaled
Correspondence: Professor RG Townley, Allergic Disease Center, 
Creighton University, 2500 California Plaza, Omaha, NE 68178, USA. 
 Received 11 October 1995. Accepted for publication 11 October 
1995.
14 RG TOWNLEY
bronchodilator therapy. Sears et al. speculate that patients pro-
tected by the regular use of β-agonist may tolerate higher expo-
sure to allergens and thus early allergic response but not the late 
response may be reduced.
 t is the late response that is associated with increased airway 
reactivity. It has long been recognized that the severity of asthma 
is associated with the degree of airway reactivity.9 This association 
has been recently emphasized by a report by O'Hollaren et al.10
Regularuse of inhaled β-agonist resulted in a mild increase in air-
way reactivity as reported by Britton and colleagues.11 However, 
the clinical relevance of this has been questioned and other inves-
tigators have reported different results. The new, long-acting β2-
agonist, salmeterol, actually decreased airway reactivity and 
completely protected against the late bronchial reaction.12 The
current availability of long-acting β-agonists has served to
heighten the controversy and the argument has not been settled.
TOLERANCE AND CONTINUOUS USE OF
β-ADRENERGIC AGONISTS AND THE THERAPEUTIC
ROLES OF THE NEW LONG-ACTING β GONISTS.
Whether the long-octing β2-agonist will be beneficial or detri-
mental will ultimately be ossessed at the clinical level. The
homologous downregulation of β-adrenergic responses in
leukocytes associated with the continuous use of β-agonists
raises the question whether the long-octing β2-agonist will only
further downregulate these β-adrenergic responses. However,
chronic administration of β-agonists in patients with asthma
usually results in no diminution of the peak bronchodilating
effect. More apparent is the decreased duration of bronchodila-
tion.13 Long-term treatment with β-agonists has not resulted in
tolerance to the bronchodilating effects of salmeterol or for-
moterol in patients with asthma. However, the finding that regu-
lar treatment with salmeterol for 4 and 8 weeks resulted in 
significant tolerance to its protective effect against the bron-
choconstrictor stimulus of methacholine is a matter of some 
concern.14 This occurred without any evidence of tolerance to its 
bronchodilating effect. The reduced protection against metha-
choline might be caused by tolerance to the functional antago-
nism caused by salmeterol. This suggests that patients on
regular monotherapy with a β-agonist may be more susceptible
to an acute bronchoconstricting stimulus. For this reason, the 
use of inhaled corticosteroids to prevent this tolerance to the
protective effect of long-acting β-agonist has been advocated.
Tolerance to the protective effect of inhaled terbutaline against 
the bronchoconstrictive effect of adenosine monophosphate 
(AMP) was even greater than for methacholine.15
 Sheppard and co-workers16 in contrast to the work of Sears et 
al.,7 found that the use of albuterol, two puffs four times a day, 
was clearly better than treatment with placebo. Other studies by 
Smith et al.17 and VandeWalker et al.18 also reported results 
opposite to those of Sears and colleagues.7 In the latter study, 
for the 2 week period, the patients using inhaled terbutaline did
better in terms of all major variables, such as asthma control, 
use of inhaled bronchodilator when needed, and both AM and 
PM peak flow rates than when using a matching placebo. The 
patients studied by VandeWalker were maintained on theo-
phylline throughout the study.18 These results argue that long-
acting theophylline may protect the patients against early 
morning exacerbations. Whether theophylline plays a role in
preventing subsensitivity to β-agonists needs to be evaluated. In
this regard, i  human blood monocytes, agents that increase
cyclic AMP such as β-adrenergic agents result in increased
phosphodiesterase IV and consequently increased metabolism 
of cAMP.19 If this proves to be true for human airway tissue, it 
would provide a rational basis for using phosphodiesterase
inhibitors in combination with β-agonists.
  Formoterol fumarat  is a catecholamine derivative with a 
formylamino-substituted catecholamine.20 Formoterol is a sec-
ond, new, long-acting β2-adrenergic agent. It was originally
developed by Yamanouchi Ltd, Japan and has been marketed 
as an oral formulation in Japan since 1986. Formoterol for 
inhalation has been developed by Ciba Geigy Pharmaceutical 
Company, Basel, Switzerland for use as a metered-dose inhaler.
Inhalation of 12-24μg of formoterol suspension caused near
maximal bronchodilation within 5 min and had a duration of up 
to 12h. The side effects observed after inhalation of formoterol 
were imilar in frequency and type to those observed with other
β2-adrenergic drugs studied. Because of its rapid onset of
action, patients using formoterol, in contrast to salmeterol,
should not need to carry a second β-agonist inhaler to obtain
quick relief.20 In several comparative trials formoterol solution
aerosol at a dose of 12μg twice daily showed greoter bron-
chodilator effects than fenoterol (200μg three times daily),
albuterol (200μg four times daily) ond terbutaline (250μg four
tim s daily).
 Formoterol is slowly washed out from tissues and is lipophilic 
but not as lipophilic as salmeterol. Formoterol is not structurally 
related to fenoterol and is two orders of magnitude more potent 
than albuterol or isoproterenol.20 Its anti-inflammatory effects are 
suggested by its ability to inhibit histamine release with an ED50 of 
10-11 mol/L. In this regard Tokuyama et al. reported that inhaled 
formoterol inhibits histamine-induced airflow obstruction and air-
way microvascular leakag .21 Because the microvascular leakage 
in small airways results in mucosal thickening, this could have a 
profound influence on the tendency of small airways to close.
THE LATE ALLERGIC REACTION AND AIRWAY
HYPERRESPONSIVENESS: THE EFFECT OF β-AGONIST
The relative ability of formoterol to protect against microvascu-
lar le k and the potentially related inflammatory response could 
play an important beneficial role in the late bronchial reaction
(LAR)where the usuol β-agonists are thought to be relatively
ineffective. Conventional β2-agonists inhibitt the immediate
all rgic response by inhibiting mast cell mediator release in
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addition to their direct bronchodilating effects. Conventional β2-
agonists have generally been demonstrated not to inhibit the 
late allergic reaction after antigen-challenge or the accompany-
ing rise in non-specific bronchial responsiveness.22,23
 We studied the effect of formoterol on the late asthmatic 
response and the airway inflammation in guinea-pigs.24 The 
appearance of the LAR and the antigen-induced airway inflam-
mation was completely suppressed by formoterol, although iso-
proterenol, a conventional short-acting β2-agonist, failed to
inhibit LAR and the increased airway inflammation. The antigen-
induced bronchial responsiveness to histamine was also 
decreased by formoterol. Formoterol has been reported to 
decrease airway responsiveness to methacholine even at 12h 
after inhalation in asthmatic children.25 Formoterol also has 
been reported to improve bronchial hyperresponsiveness to his-
tamine and cold air after long-term administration. Given before 
antigen-challenge, both formoterol and salmeterol have been 
shown to attenuate the LAR in patients with asthma.12,26,27 
 It has not been determined whether these inhibitory effects of 
formoterol and salmeterol on LAR and airway inflammation are
due to the persisting action of β2-receptor stimulation or some
additional anti-inflammatory mechanism. The effect of inhaled
corticosteroids atone and in combination with long-acting β2-ago-
nists on the clinical response, the LAR, the BAL inflammatory 
response and the airway hyperresponsiveness needs to be studied.
THE EFFECT OF CORTICOSTEROIDS ON
β-ADRENERGIC RESPONSES
In addition to the anti-inflammatory effects of corticosteroids, the
effect of glucocorticoids on pulmonary β-adrenergic receptors
and responses suggests an important role for glucocorticoids in
increasing β-adrenergic receptors and responsiveness.28
Glucocorticoids lower the threshold of the relaxation response of
β-adrenergic receptors and inhibit the α-adrenergic contractile
response to catecholamines in isolated tracheas from humans 
and guinea-pigs.29,30 Glucoconccoids can reverse the homolo-
gous downregubtion Qnd decreosed responsiveness to β-adren-
ergic agonist induced by chronic  treatment with β-agonist drugs
in the airways of normal31 and asthmatic subjects.32 The stimula-
tion of adenylate cyclose by β-adrenergic agonists are poaenti-
ated by glucocorticoids in human leukocytes33 and canine 
tracheal smooth muscle.34 A significant increase in the density of
leukocyte β-receptors, beginning on day 2 without a significant
change in the dissociation constant, was observed with oral 
prednisone 15mg three times daily for five days. We also 
observed that pulmonary function improved, granulocyte cAMP 
doubled, and the increased neutrophil and decreased eosinophil 
and lymphocyte counts changed as expected.35
The density of β-receptors in the lung increased by 70% after
chronic administration of hydrocorfisone in animals.28 Adrenal-
ectomy produced the opposite effect with a 29% fall in the density
of β-receptors without altering the aff ity for β-receptors.
Glu ocorticoids also increase adrenergic responsiveness36 and the
density of β-receptors37 in human lung cells in culture. These find-
i gs suggest that glucocorticoids potentiate β-adrenergic receptor
stimulation, at least in part, by increasing β-receptor density.
ADRENERGIC RECEPTORS: STRUCTURE AND FUNCTION
A new approach to studying receptor regulation in inflammatory 
cells in lung disease has been provided by new insights into 
receptor structure function and the cloning of many receptors. 
The genes for neurotransmitters, cytokines and the various 
adrenergic receptors have now been cloned and expressed. This 
has also led to an understanding of the parts of the protein struc-
ture that are involved in ligand binding, signal transduction and 
receptor regulation. It is now possible to study the pharmacology 
of th  receptors in a cultured cell line. The deletion of specific 
nucl otide sequences in the receptor gene has made it possible 
to produce mutant receptors by a process called deletion muta-
genesis. The understanding of the function of various parts of the 
receptor molecule has advanced rapidly due to the cloning of 
mutant receptors. Partly as a result of receptor cloning and the 
development of selective antagonists, the discovery of related
subtypes of receptors such as the three subtypes of β-adrenergic
and seven subtypes of α-adrenergic receptors has occurred.
 Changes in the target organs of asthma and the allergic 
response caused by adrenergic agonists are elicited by the inter-
action of the adrenergic agonists with cell-membrane receptors 
that are coupled to intracellular guanine nucleotide-binding reg-
ulatory proteins, designated G proteins. The effect of adrenergic 
agents on their specific receptors is mediated by these G proteins 
an  the signal transduction generated. G proteins are composed
of α, β and γ subunits and hove been extensively reviewed by
Gilman38 and by Fraser.39 Following β-agonist binding, G pro-
tein coupled receptors are changed in their conformation and
GTP replaces GDP with the α subunit on the G protein. The
activity of the various effector systems results when there is a dis-
sociotion of the α subunits from the β and γ subunits. These effec-
for systems include not only effects on adenylate cyclase and 
CAMP but on a number of other systems including ion channels, 
cyclic GMP phosphodiesterase and phospholipases. These
Table 1. Cellular effects of β2-adrenergic receptor stimulation
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various changes result in metabolic and ion changes within the 
cell or on the cell surface which will have a variety of physiologi-
cal consequences not only on airway smooth muscle but on the 
wide array of cells in the airway and the inflammatory cells asso-
ciated with the allergic response. (Table 1). 
 Molecular cloning and molecular biology with sequence 
analysis of the genes encoding these G proteins and the various
subtypes of receptors, including β1-, β2- and β3-adrenergic
receptors as well as α1A-,α1B-,α1c-,α2A-,α2B-,α2c- andα2D-
adrenergic receptors, provide a much greater complexity, as well 
as a greater understanding, of the functional interaction among 
the various G proteins and the various adrenergic receptors. 
There is a high degree of homology between the various adren-
ergic receptor subtypes in terms of the amino acid sequences
that span the transmembrane do ain in the seven α helices of
the receptors. The adrenergic receptors are, for the most part, 
glycoproteins. These various adrenergic receptors all have in 
common seven membranes spanning amino acid sequences.
 Asthma symptoms, bronchial hyperreactivity, the level of IgE 
and the genes for interleukin (IL) 3, IL-4, IL-5, IL-13 and GM-CSF 
have been linked to an area of chromosome 5q31-32.40 The 
gene for the β2-adrenergic receptor has also been localized to
human chromosome 5q31-32 which is the same region for the
α1B-receptor. lf there was some genetic defect in asthmo at the
respective chromosome sites for β2 and α1B as mentioned above,
this could result in physiological antagonism. Thus, the interest-
ing hypothesis thatthere could be an imbalance between the α-
and β-adrenergic receptor function in asthma may now be
testable at the molecular and genetic level. Much less is known
about the β3-adrenergic receptor other thon it hos a much lower
affinity for β-adrenergic antagonist and for co echolamine ago-
fist, and it appears to play a functional role in tissues such as 
muscle and adipose with a particular distribution to brown and 
white adipose tissue.
REGULATION OF ADRENERGIC RECEPTORS
That glucocorticoids produce a marked increase inthe β-adren-
ergic receptor density in lung cells has been recognized for a
number of years.28,41 This increase in β-receptors by cortico-
steroids is due to an increase in the level of a receptor-specific
mRNA and the genes for the β-adrenergic receptors contain
DNA binding sites for glucocorticoid receptors.42 The effect of
β-adrenergic ogents on β-receptors and the desensitization of
receptors that occurs has important implications in the therapy
of asthma, particularly in the use of potent long-acting β-
agonist. This effect on the regulation of adrenergic receptors is
very germone to the controversy on the regulor use of β-ago-
fists versus an intermittent or demand basis. This prolonged
exposure of β-receptors results in receptor phosphorylation and
is associated with impaired receptor-G-protein coupling.43 
Sibley and Lefkowitz have also reported that phosphorylation of
3-receptors by prolonged exposure to B-agonist may increase
their internalization from the cell surface and, therefore, make
them unovoilQble for activation by β-adrenergic agonists.43
  A β-adrenergic receptor kinase hos been identified (BARK)44
and i  cyclic-AMP-independent. BARK results in agonist-specific 
or homologous desensitization of the receptor. Activation of 
ade ylate cyclase by a variety of mechanisms, including hista-
mine acting through H2 receptors or prostaglandin E with stimu-
lation of adenylat  cyclase, results in activation of the protein 
kinases A and C and provides feedback mechanisms of desen-
sitization. This type of regulation known as heterologous desen-
sitization may be an important mechanism in the decreased 
cyclic AMP response that occurs in the lymphocytes of patients 
with asthma following allergen-challenge and the associated 
late reaction with airway hyperresponsiveness as reported by 
Meurs et a1.45 This heterologous desensitization at the cellular 
level has been demonstrated in various in vitro preparations.46,47 
Important opportunities are now present in terms of advancing 
our understanding of the autonomic deregulation in asthma 
and the interaction of the inflammatory response as a result of 
the allergic reaction. This has occurred due to the tremendous 
advance in understanding the diverse types of adrenergic recep-
tors at their genetic and molecular level.
INTERACTION OF α-AND β-ADRENERGIC
MECHANISMS
The administrotion of an α-agonistsuch as methoxamine pro-
vokes airway narrowing.48 It has been observed that α-adrenergic
responsiveness, following the administration of phenylephrine,
Fig. 1 Effect of epinephrine on human trachea relaxation response.
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was increased only in patients with asthma compared with 
normal subjects and patients with allergic rhinitis.49 Further studies 
involving the autonomous imbalance in asthma can address the 
controversy regarding the role of adrenergic receptors in asthma. 
  The presence of a-adrenergic receptors on human airways
has been determined. The α-adrenergic receptors have been
tested for in the presence of β-adrenergic blocking agents to
avoid the contribution of β-receptor stimulation thatcould have
a counter-regulatory effect. The human tracheal smooth muscle 
was contracted by epinephrine in the presence of propranolol30
(Fig. 1). In the presence of hydrocortisone or α-adrenergic
blockers (phentolamine, phenoxybenzamine) the contracting 
effect of epinephrine was reduced or abolished.30 In patients 
with chronic obstructive lung disease, airway smooth muscle
showed a greater direct responsivenessto α-agonistthan airway
smooth muscle from normal individuals.50 Normal individuals 
only showed a-adrenergic contraction of the smooth muscle
when the smooth muscle was already partially depolarized by 
histamine or potassium chloride. Thus, it appears that the effect
of an α-agonist on contraction is enhanced if the airway smooth
muscle is partially depolarized. The possibility exists that an
increased α- and decreased β-receptor activity occurs in
patients with asthma following repeated exposure to allergens 
and the associated inflammat ry response.
SITE-DIRECTED MUTAGENESIS
Understanding the structure and function of receptors has been 
accelerated by using the technique of site-directed mutagenesis 
(Fig. 2). Studies using deletion mutagenesis, where stretches of 
the amino acid sequence are removed, indicate that the third
intracellular loop is critical for interaction between β2-receptors
and GS.51 
 Mutations of small regions or even single amino acids of the
Fig. 2 Adrenergic receptor mutations found in patients with and without asthma. The darkened circles indicate where nucleic acid changes were 
detected. Regions of amino acid change ('missense mutations') are indicated by the amino acid substitutions (e. g., Arg 16-Gly). Of the nine muta-
tions found, five resulted in no amino acid changes, while four resulted in changes in the encoded residues indicated at amino acid positions 16, 27, 
34, and 164. Kindly provided and modified by Liggett.53
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β2-adrenergic receptor can affect receptor function. Recent
studies show that there are at least six different mutations or
polymorphic forms of β2-adrenergic receptors. While these
mutations are not the primary cause of asthma, they may 
account for some of the clinical heterogeneity among patients 
with asthma. Whether such mutations occur, and their impor-
tance in the pathogenesis of asthma and the patient's response 
to therapy has been studied by Liggett and colleagues.52,53
These investigators developed a method of studying β2-
adrenergic receptor mutations.52 The lymphocytes of 56 healthy 
people and 51 patients with moderately severe asthma were 
used to isolate the genomic DNA. This method involved identi-
fying a single amino acid deviation from the wild-type β2-adren-
ergic receptor coding sequence using temperature-gradient gel 
electrophoresis. 
 There was no difference between patients with asthma and 
the controls in the frequency of distribution of both homozygous 
and heterozygous polymorphisms in this group. The distribution
of β2-adrenergic receptor mutations in the two populations
studied is shown in Fig. 2.53 Darkened residues indicate the nine 
regions of DNA mutations; there were no changes in the 
encoded amino acids at five of these colons. However, four 
mutations did cause changes in the encoded residues. These 
mutations are indicated at amino acid positions 16, 27, 34 and 
164. Liggett and colleagues noticed a clustering of patients with 
Arg 16 to Gly polymorphism in 75% of asthma patients who 
were corticosteroid dependent. This was defined as the need for 
prednisone 20mg daily for more than 6 months. These authors 
found a number of abnormalities when they compared this
mutated recep+or with the wild-type β2-adrenergic receptor.54
The over-representation in patients with nocturnal asthma of
one such abnormality is the Gly 16 polymorphism of the β2-
adrenergic receptor mutation which results in enhanced down-
regulation of receptor number.55 The frequency of the Gly 16 
allele was 80.4% in the nocturnal group compared with 52.2% 
in the non-nocturnal asthma group (P=0.007; Fig. 2).
An association of Glu 27 β2-adrenoceptor polymorphism
with a four-fold lower airway reactivity to methacholine com-
pared with the wild-type Gin 27 genotype in a study of 65 
patients with asthma has also been reported by Liggett and col-
leagues.56
THE ACTION OF G PROTEINS IN AIRWAY SMOOTH 
MUSCLE AND ASTHMA
One hypothesis for the increased sensitivity of airway smooth 
muscle to contractile agonists in patients with asthma could be
the reduced sensitivity of β-adrenoreceptor-induced excitation-
contraction uncoupling in the airway. This could be a conse-
quence of aberrant G protein regulation of adenylyl cyclase.57 
Because of the increased number and activity of inflammatory 
cells in the airways of asthma patients, mediators could be 
released that are capable of activating protein kinase C, which
in turn would phosphorylate GS and subsequently alter agonist-
stimulated adenylyl cyclase. These authors have postulated that 
GS has been shown to be a substrate for phosphorylation by 
protein kinase C and this phosphorylation is likely to elicit a pro-
found inhibitory effect on subsequent GTP-stimulated adenylyl 
cyclase activlty.57
Meur  et al. evaluated the regulation of the β-receptor-
adenylate cyclase system in the lymphocytes of allergic patients 
with asthma and the possible role of protein kinase C in aller-
gen-induced, non-specific refractoriness of adenylate cyclase.58 
Their work supports the concept of G protein coupling abnor-
mal ties in asthma. After a late reaction induced with an aller-
gen challenge, the lymphocytes of allergic individuals showed a 
decreased adenylate cyclase activity as well as decreased CS
protein responses to β-agonist, prostaglandin E and GTP
an logs.
It has been suggested that there might be a defect in the β-
adrenoreceptor function or G protein coupling in asthma since
β-adrenergic blocking agents, including inhalation of propra-
nolol, cause bronchoconstriction in patients with asthma but not
n normal subjects.59 A possible defect in β-receptor function in
airway smooth muscle has been suggested since several studies 
have d monstrated that airways from patients with asthma fail 
to relax normally to isoproterenol,60-62
β-ADRENERGIC RECEPTOR FUNCTION IN THE TARGET
TISSUES OF ASTHMA
Isoproterenol is a more potent relaxant in intact airway epithe-
lium than in epith lium that has been damaged, for example, by 
eosin phils as occurs in clinical asthma or in the late reaction.63 
Damage or partial denudation of the airway epithelium results 
in a loss of epithelial-derived relaxant factor.64 If the airway 
epithelium is damaged bronchial reactivity is increased. As
stated, the loss of epithelium also results in the loss of β2-adren-
ergic receptors and is consistent with the decreased response to
β2-agonists n inflamed airway mucosa as occurs in the late
reaction. β2-Adrenergic receptors increase cAMP levels and
CAMP regulates the permeability of epithelial tight junctions.
With intact airway epithelium β-adrenergic receptors maintain
the integrity of tight junctions and thus regulate the ion and the 
fluid transport across epithelium cells (Table 1).
The effect ofthe β2-adrenergic receptor agonists in asthma may
also be related to their effect on alveolar macrophages, since 
macrophages contain a number of mediators including 
leukotriene B4 and C4, platelet-activating factor, IL-1, tumor 
necrosis factor, superoxide anions and hydrogen peroxide. 
Human alveolar macrophages obtained by bronchial alveolar
lavage contain about 5600 β2-adrenergic receptors with a Kd of
about 29mol/L65 Stimulatian of these β2-receptors with isopro-
terenol results in a six-fold increase in cAMP production. All of 
these mediators, as well as fibronectin mediated phagocytosis and 
phago ytosis of immune complexes, can be modulated by cAMP.
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In this regard, the activation of β2-adrenergic receptors and the
increase in cAMP may inhibit the migration and release of lysoso-
mal enzymes and mediators from alveolar macrophages.66,67
β-Adrenergic agonists regulate many aspects of lung function
in addition to their potent effects on airway smooth muscle. 
These effects include the regulation of fluid and ion transport 
across epithelial cells, the inhibition of microvascular perme-
ability and the inhibition of mast cell degranulation (Table 1).68
THE EFFECT OF β-ADRENERGIC BLOCKING AGENTS,
DIMINISHED cAMP RESPONSE AND AUTONOMIC 
DYSREGULATION
The known contraindication of using β-adrenergic blocking
agents and the diminished cyclic AMP response to β-adrenergic
agonists are two characteristic features of asthma. It has long
been recognized that β-adrenergic blockade accentuates the
immediate response to an allergen, as well as to mediators that 
act directly on smooth muscle, such as histamine, methacholine 
and serotonin.69 The effect of these agents on the late reaction
has not been studied. β-Adrenergic blockade increased the sen-
sitivity to histamine, methacholine and serotonin in guinea-pigs
and mice.69 However, in this same study β-adrenergic blockade
had a much greater effect on the sensitivity to an antigen. This
may be due to the location of β-adrenergic receptors on a wide
variety of the target tissues of asthma and not just the airway 
smooth muscle (Table 1).
β-Adrenergic hyporesponsiveness, and cholinergic and α-
adrenergic hyperresponsiveness have been implicated in the eti-
ology and pathogenesis of asthma.68 These changes have been 
interpreted by other investigators as being secondary to the dis-
ease process rather than a primary determinant.70
lnhalation of β-blockers alone has been used as a bron-
choconstrictor-challenge test in suspected asthmatic subjects. In 
asthmatic subjects, pretreatment with propranolol potentiates 
the bronchoconstriction caused by histamine,71 methacholine,72 
acetylcholine,73 and cigarette smoke.74 However, in normal 
subjects the bronchomotor response to methacholine75 or to 
histamine76 was not increased by pretreatment with propranolol. 
In contrast, subjects with allergic rhinitis who were insensitive to 
methacholine developed a transient sensitivity to methacholine 
and symptoms of asthma after propranolol inhalation.75 In pro-
pranolol-induced bronchoconstriction, it is believed that unop-
posed parasympathetic tone may be involved since atropine 
prevents and partially reverses this effect in patients with mild 
asthma.77
EFFECT OF THE ALLERGIC REACTION, CYTOKINES
AND PAF ON β-ADRENERGIC RESPONSES
Altered adrenergic responsiveness and decreased number of β-
adrenergic receptors in patients with asthma has been reported 
by several groups of investigators;78-81 however, the evidence
would indicate a defect beyond the β-receptor itself. Other
investigators have also demonstrated that antigen-challenge of
sensitized guinea-pigs in vivo resulted in diminished in vitro β-
adrenergic receptor mediated relaxation of airway smooth
muscle.82 The effect of pro-inflammatory cytokines TNF-α, IL-1β
or IL-2 was also studied by these investigators (Fig. 3). None of 
th se cytokines affected the contractile response of trachea to 
carbamylcholine; however, the relaxation response to isopro-
terenol was significantly reduced by TNF-α and IL-1 β but not by
IL-2. These observations led to the conclusion that pro-inflama-
tory cytokines can result in diminished β-adrenoceptor function
as seen in the antigen-challenge guinea-pig model.82
 Interleukin-1 causes the synthesis of PAF by vascular endothe-
lial cells.83 PAF can activate eosinophils to release superoxide 
a d leukotrienes.84 PAF can cause bronchoconstriction, inflam-
mation and edema, and chemotaxis of inflammatory cells, espe-
cially of osinophils.84 We have demonstrated that in vitro 
incub tion of human lung tissue with PAF decreases the density
f β-adrenergic receptors in human lung membranes.83,85 PAF
has also been reported to induce a decrease in the density of
β-receptors in othertissues.86 In functional studies of isolated tra-
chea and lung parenchyma of guinea-pig or human, PAF signif-
ic ntly reduced the potency of isoproterenol to reverse 
met acholine or histamine induced contraction. These changes 
were pro ected against by a specific PAF receptor antagonist 
BN52021 83,85,87 PAF aerosol potentiated the increase in specific 
airway resistance produced by methacholine in our in viva stud-
ies in guinea-pigs. In contrast, the reversal of this airway obstruc-
tion by isoproterenol or prostaglandin E2 was diminished.87 This 
d creased response to bronchodilators could lead to increased
Fig. 3 Effects of pro-inflammatory cytokines on isoproterenol-induced 
relaxation of cultured tracheas. Relaxation was expressed as percentage
of the maximal contraction to carbamycholine.
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non-specific airway hyperresponsiveness. These animal studies
of PAF-induced airway hyperresponsiveness and decr ased β-
adrenergic responses suggest a possible role for PAF in asthma; 
however, recent studies in man do not support this. A potent PAF 
antagonist WEB-2086 failed to protect against the antigen-
induced late bronchial reaction in man.88
 The interaction of leukotrienes and adrenergic responses 
needs further evaluation. In this regard, leukotrienes B4 and C4
reduce β-receptor binding and isoproterenol-induced activation
of adenylate cyclase in lymphocytes.89
 Lymphocytes, particularly helper T cells type II, play a primary 
role in orchestrating the immune response in the airways. 
Production of various lymphokines such as IL-3, IL-4 and IL-5 
are very important in mast cell, basophil and eosinophil growth 
and differentiation. Future studies comparing physiological
effects of β-agonists on the release of these lymphokines, as
well as the effect of IL-1,TNF-α and other cytokines on β-adren-
ergic receptors could be very important in understanding the
interaction of β-receptors with cytokines.
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